Facing patent cliffs, drug developers are aggressively changing the way they do R&D, says Tufts

6 January 2011

With dozens of prescription drugs due to lose their patent protection over the next several years, and few likely blockbusters in company pipelines to replace declining revenue, pharmaceutical companies are aggressively changing the way they do R&D, according to the Tufts Center for the Study of Drug Development.

Noting that developers are looking to reduce development time, cut costs, and improve operating efficiency, Tufts CSDD Director Kenneth Kaitin said: "The research-based drug industry, in the United States and globally, is not sitting still, but the question remains whether developers can bring enough new drugs to market at the pace needed to remain financially viable." He made his comments in connection with the release of the Tufts Center's Outlook 2011 report on pharmaceutical and biopharmaceutical trends.

Development cost of a new drug now $1.3 billion

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology